ESTRO 2024 - Abstract Book

S52 ESTRO 2024 underscore the need for robust validation studies and standardized methodologies in genetic risk profiling. Furthermore, ethical considerations regarding genetic testing, data privacy, and informed consent necessitate careful deliberation to ensure equitable access and patient autonomy in personalized radiotherapy approaches. Some studies also propose to move the focus of investigation about individual radiosensitivity from the genetic level to a phenotype level. Particularly, the role of gut, salivary, skin and lung microbiota, together with the inflammatory environment, seem pivotal. There is an evolving landscape for integrating biological patient-specific information in models for predicting side effects after radiotherapy. Methodological approaches also highlight clinical implications for personalized treatment strategies, advancing the precision oncology paradigm. Invited Speaker

3363

Individualised dose-prescription for stage 3 NSCLC

Ohri Nitin

Montefiore Einstein Comprehensive Cancer Center, Radiation Oncology, Bronx, USA

Abstract:

Current evidence-based practice is to treat stage III non-small cell lung cancer (NSCLC) patients with a uniform radiotherapy dose, irrespective of specific patient and disease characteristics. However, stage III NSCLC is now known to include a wide range of disease entities, which may be defined based on disease burden and distribution as well as tumor biomarkers. Emerging evidence suggests that selected stage III NSCLC patients may benefit from advanced radiotherapy techniques, personalized radiotherapy dose prescriptions, and novel combinations of systemic therapy and radiotherapy. We will review data supporting personalized treatment of stage III NSCLC, ongoing trials testing innovative treatment approaches, and promising areas for future study.

3364

Innovative drug-radiotherapy trials

Antonin Levy

Gustave Roussy, Radiation Oncology, Villejuif, France. Université Paris Saclay, INSEM U1030 Lab, Molecular Radiotherapy, Villejuif, France. Université Paris Saclay, Faculé de Médecine, Le Kremlin BIcetre, France

Abstract:

Newer technical improvements in radiation oncology have been rapidly implemented in recent decades, allowing an improved therapeutic ratio. Targeted therapy and immune checkpoint blockers are increasingly being incorporated as the new standard of care for a wide array of cancers. Novel drug-radiotherapy combinations represent a promising